Medicine and Dentistry
Positron Emission Tomography-Computed Tomography
100%
Fluorodeoxyglucose F 18
39%
Computer Assisted Tomography
33%
Breast Cancer
27%
Prostate Cancer
25%
Positron Emission Tomography
21%
Fluorine-18
20%
Gallium 68
19%
Fluorodeoxyglucose
18%
Neoplasm
17%
Disease
16%
Positron Emission Tomography
15%
Radiation Therapy
15%
Prostate Specific Membrane Antigen
14%
Cancer
13%
Diagnosis
13%
Metastatic Carcinoma
10%
Stereotactic Body Radiation Therapy
9%
Recurrent Disease
9%
Malignant Neoplasm
8%
Standardized Uptake Value
7%
Pelvis
6%
Biochemical Recurrence
6%
Continuous Positive Airway Pressure
6%
Immune Checkpoint Inhibitor
6%
Deoxyglucose
6%
Pediatrics
6%
Fibroblast
6%
Protein Inhibitor
6%
Biopsy
6%
Lymph Node
5%
Psoriasis
5%
Colorectal Cancer
5%
Rituximab
5%
Progression Free Survival
5%
Keyphrases
Positron Emission Tomography-computed Tomography (PET-CT)
88%
18F-FDG PET-CT
22%
Prostate-specific Antigen
17%
Fluorodeoxyglucose
16%
FDG Uptake
15%
18F-fluorodeoxyglucose (18F-FDG)
13%
Prostate
11%
SUVmax
11%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
11%
Computed Tomography
11%
Lymphoma
11%
Breast Cancer Patients
11%
FDG PET-CT
10%
PET-computed Tomography
10%
Pitfalls in Interpretation
9%
Prostate Cancer Patients
9%
Prostate Cancer
8%
Breast Cancer
8%
Standardized Uptake Value
8%
Invasive Lobular Breast Cancer
7%
Positron Emission Tomography
7%
Gallium-68
6%
Postoperative Changes
6%
High Risk
6%
PSMA PET-CT
6%
Chemotherapy
6%
FDG-PET Scan
6%
Radionuclide Therapy
6%
Fibroblast Activation Protein Inhibitor
6%
Invasive Breast Cancer
6%
Immune Checkpoint Inhibitors
6%
Membrane Antigens
6%
Fluorine-18
6%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
6%
Continuous Positive Airway Pressure
6%
Lutetium-177 (177Lu)
6%
Prostate-specific Membrane Antigen Positron Emission Tomography
5%
CT Findings
5%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
5%
Malignancy
5%
Tumor
5%
Tumor Size
5%
Biochemical Failure
5%
Histological Subtypes
5%
Rituximab
5%
Progression-free Survival
5%
Psoriasis
5%
Tertiary Care Hospital
5%